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Edited by Varda RotterAbstract In this study, we report that the human p14ARF asso-
ciates in vivo with the N-Myc and inhibits N-Myc mediated tran-
scriptional activation. We have determined that the region (aa
140–300) encompassing the N-Myc BoxIII is required for eﬃ-
cient interaction in vivo. Furthermore, we demonstrate that in
the SK-N-BE neuroblastoma cell line p14ARF over-expression
delocalized N-Myc from the nucleoplasm into nucleoli and that
N-Myc regions required for interaction with p14ARF are also
important for nucleoli co-localization. Finally, we determine that
the N-terminal region of the p14ARF protein is involved in binding
to c-Myc and N-Myc proteins.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Genes of the Myc family contribute to the genesis of several
types of human tumors. In all cases, Myc expression is in-
creased in the tumors indicating that Myc elevated expression
contributes to tumorigenesis [1,2]. N-Myc and c-Myc have dif-
ferent patterns of gene expression; whereas c-Myc is expressed
during embryonic development and in adult tissues, N-Myc is
found in undiﬀerentiated types of cells in the lung, heart, ner-
vous system, kidney, limbs, etc. [3,4].
N-Myc oncogene is implicated in the pathogenesis of neural
crest derived tumors including neuroblastoma, the most fre-
quent solid malignancy in infants. Ampliﬁcation of N-Myc
gene is the major negative prognostic marker in human neu-
roblastomas [5,6]. Although N-Myc and c-Myc share large re-
gions of sequence conservation, their physiological role in the
cell does not seem redundant since gene inactivation studies
have shown that functional loss of either c-Myc or N-Myc
leads to embryonic lethality [4,7–9].
Myc proteins act as transcription factors, although c-Myc
transcriptional activity has been well characterized and several
co-activators have been found, much less is known about*Corresponding author. Fax: +39 081 679233.
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doi:10.1016/j.febslet.2007.01.062N-Myc co-factors mainly because of the assumption that
c-Myc and N-Myc have redundant functions [1,10].
Among c-Myc partners, the tumor suppressor protein ARF
(alternative reading frame) has been found to directly bind the
Myc protein and dramatically block c-Myc’s ability to activate
transcription and induce hyperproliferation and transforma-
tion [11–13].
Although ARF is not detectably expressed in most normal
tissues, increased levels of mitogenic signals or aberrant
expression of oncogenes induce the transcription of ARF. In
particular, c-Myc was the ﬁrst oncogene to be found to acti-
vate ARF that in turns, in order to induce cell cycle arrest,
must functionally inhibit cell cycle regulated gene expression
[14,15]. The p14ARF protein has both p53-dependent and
p53-independent tumor-suppressive activities. In a p53 back-
ground, ARF antagonizing the E3 ubiquitin ligase activity of
MDM2 determines the stabilization of p53 incrementing its
transcriptional activity; the result is the induction of cell-cycle
arrest or apoptosis [15]. More recently, several ARF p53 inde-
pendent functions have been documented. In particular, ARF
has been shown to associate with transcription factors as
Foxm1b, E2F, DP1, c-Myc, all of them directly involved in
the regulation of cell cycle genes expression [11,15–17].
Given the similarity between N-Myc and c-Myc proteins but
also the striking divergence among their expression pattern, we
were interested to determine whether p14ARF interacts and reg-
ulates N-Myc. We found that p14ARF binds N-Myc in vivo
and inhibits N-Myc transcriptional activity. We also found
that ARF over-expression in neuroblastoma cells delocalizes
the N-Myc protein from the nucleoplasm to the nucleoli where
it co-localizes with ARF. We have mapped the N-Myc region
involved in ARF binding in the central region of the protein
(aa 140–300) and we have demonstrated that N-Myc mutants
that do not interact with p14ARF are not recruited into nucleoli
upon ARF co-expression. Finally, we mapped in the N-termi-
nal region of the p14ARF protein the domain involved in c-Myc
and N-Myc binding, respectively.2. Materials and methods
2.1. Plasmids
pcDNA3-N-Myc, N-Myc d(1–300), N-Myc d(1–134), N-Myc d(20–
90), and N-Myc d(96–140), N-Myc d(350–464), N-Myc d(350–464)
were kindly provided by Dr. T. Fotsis [18]. pCMV14-N-Myc and
GFP-p14ARF have been previously described [19,13]. F:p14ARF,
F:p14ARF(1–65), and F:p14ARF(65–132) were obtained by subcloning
the corresponding cDNA ARF coding sequences into the
p3XFLAG-CMV10 vector (Sigma).blished by Elsevier B.V. All rights reserved.
Fig. 1. ARF expression inhibits N-Myc activated transcription.
Tet21Ncells were cotransfected with 100 ng of hTERT-Luc and
diﬀerent amounts (0.1; 0.5 and 1 lg, respectively) of F:p14ARF, as
indicated. N-Myc was activated by tetracycline withdrawal. Each
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Human 293 T, SK-N-BE and Tet-21/N cell lines were grown in
DMEM supplemented with 10% fetal calf serum. Tet-21/N cells [19]
were maintained in the presence of tetracycline (1 lg/ml) for at least
one week before transfection. 1 · 105 cells/well were plated and grown
for an additional 24 h in 6 well plates in the presence of tetracycline.
The cells were washed with 1· PBS and then transfected with the appro-
priate constructs by the polyethylenimine (PEI 25 K) method as de-
scribed [20]. After transfections, the cells were incubated for 48 h in
presence or absence of tetracycline as required. The activity of ﬁreﬂy
was measured with the dual luciferase assay kit (Promega) according
to the manufacturer’s instructions by using a T20/20 luminometer
(Turner Design). pRL-CMV (Promega) was co-transfected for normal-
ization. The amounts of transfected plasmids DNAs are indicated in the
legend to ﬁgures. For immunoﬂuorescence analysis, SK-N-BE cells
were transfected with lipofectamine with 600 ng each of GFP-p14ARF
and/or pcDNA3-N-Myc or pcDNA3-N-Myc d(1–300) plasmids and
the cells were processed for immunoﬂuorescence as described [13] using
the N-Myc (C2, Santa Cruz Biotechnology) antibody.
2.3. Antibodies and co-immunoprecipitations
The following antibodies were used for the immunological
techniques: anti-Myc (N262 for IP and 9E10 for WB, Santa Cruz Bio-
technology, Inc.), anti-Max (C17, Santa Cruz Biotechnology, Inc.),
anti-ARF (C-18, Santa Cruz Biotechnology, Inc.), and anti-N-Myc
(C2, Santa Cruz Biotechnology). Co-immunoprecipitations from tran-
siently transfected cells were carried out as previously described [13].
All interactions were carried out overnight at 4 C. The beads were
washed at least ﬁve times using buﬀer F (10 mM Tris–HCl, pH 7.5,
150 mM NaCl, 30 mM Na4O7P2, 50 mM NaF, 5 lM ZnCl2, 0.1 mM
Na3VO4, 1% Triton and 0.1 mM PMSF) before loading on SDS–
PAGE.histogram bar represents the mean of three independent transfections
made in duplicate with a standard deviation less than 10%.3. Results and discussion
3.1. p14ARF over-expression inhibits N-Myc transcriptional
activity
It has been recently shown that ARF could inhibit c-Myc’s
ability to activate transcription [11–13]. We sought to deter-
mine whether p14ARF might aﬀect the transcription activity
of N-Myc. To this end, we used a well characterized inducible
cell line Tet-21/N, a human neuroblastoma cell line in which
N-Myc expression is controlled through a Tet-oﬀ inducible
promoter [19]. Tet-21/N cells were co-transfected with the
hTERT-Luc construct and an expression vector for p14ARF.
N-Myc induction was obtained by tetracycline withdrawal
and the cell extracts were analyzed for the human Telomerase
promoter (hTERT) driven luciferase expression. As reported
in Fig. 1, p14ARF inhibits in a dose-dependent manner the
N-Myc mediated activation of the human TERT promoter
[21], while no eﬀect was observed on basal expression of the
hTERT promoter. Moreover, co-transfection experiments per-
formed in the p53 null H1299 cell line gave similar results indi-
cating that the decrease of N-Myc mediated transcription by
ARF does not involve p53 (data not shown).
3.2. N-Myc associates with p14ARF in vivo
We have previously demonstrated that p14ARF directly asso-
ciates with the c-Myc protein. Even if it is a general assump-
tion that the interaction partners of c-Myc are also N-Myc
partners, the failure of expression of either of the two Myc
family members is not redundant and it cannot be excluded
that they can form diﬀerent complexes with their interactors.
To investigate the physical interaction between p14ARF and
N-Myc, Co-immunoprecipitation assays were performed with
protein extracts from 293T transiently transfected cells. Thecells were co-transfected with pcDNA3-N-Myc along with
F:p14ARF (F:ARF) and nuclear extracts were prepared and sub-
jected to CoIP as reported in Fig. 2. IPs were carried out using
either the N-Myc or the ARF antibodies, and the immunopre-
cipitated materials were analyzed by Western blotting with
anti-N-Myc and anti-FLAG antibodies, respectively. The re-
sults reported in Fig. 2A showed that p14ARF co-immunopre-
cipitated with N-Myc. In the converse experiment (Fig. 2B),
using the ARF antibody for immunoprecipitation, N-Myc co-
precipitated with ARF, whereas control IgG did not.
To identify N-Myc sequences involved in N-Myc-ARF
interaction, we carried Co-IP analysis using protein extracts
from 293T cells transiently co-transfected with F:ARF expres-
sion vector and several N-Myc deletion mutants as indicated in
Fig. 3B. The protein extracts were immunoprecipitated with
the ARF antibody and the Co-IP proteins analyzed by WB
with N-Myc and FLAG antibodies, respectively. As shown
in Fig. 3A, the N-Myc deletion mutant d(1–300) did not asso-
ciate with p14ARF (lane 10), suggesting a crucial role of the N-
terminus portion of the protein in ARF-binding. However,
deletions of either BoxI d(20–90) or BoxII d(96–140) retained
ARF-binding. The strength of interaction of the d(20–90) and
d(1–134) mutants was reproducibly higher than that of the
other N-Myc deletions; we do not have an explanation for this
behavior but we can speculate that these deletions could better
expose the N-Myc domain for ARF binding. From these data
we conclude that the N-Myc region involved in p14ARF inter-
action resides in the region from aa 140 to 300.
3.3. p14ARF induces N-Myc nucleolar co-localization
It has been shown that c-Myc and ARF co-localize in the
same cellular compartment upon ARF over-expression (11–
Fig. 2. p14ARF interacts with N-Myc in vivo. 293T cells were transfected with F:ARF in the presence or absence of pcDNA3-N-Myc, as indicated.
(A) Protein extracts were IP with the N-Myc antibody or preimmune antiserum (IgG) as negative control, and the co-puriﬁed complexes were
analyzed by WB with N-Myc and FLAG antibodies, as indicated. (B) The same protein extracts utilized in panel A were IP with the ARF antibody
and the Co-IP complexes were analyzed by WB with N-Myc and FLAG antibodies. Five percent of protein inputs were loaded as shown.
Fig. 3. Mapping the N-Myc domain involved in ARF binding. (A) 293T cells were co-transfected with F:ARF and a series of N-Myc deletion
constructs as indicated. Protein extracts were IP with the ARF antibody or with preimmune antiserum (IgG) as negative control. (B) Schematic
representation of the N-Myc full-length protein and deletion mutants. The relative strengths of interactions with p14ARF are indicated.
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the same cellular compartment, SK-N-BE cells were transfec-
ted with the N-Myc expression vector alone or in combination
with the GFP-p14ARF. In cells transfected with N-Myc the
protein was found exclusively in the nuclear compartment
while the GFP-p14ARF showed a predominantly nucleolar
localization (Fig. 4, panel A). In cells co-transfected with the
two expression vectors, the GFP-p14ARF protein retains the
nucleolar localization while the N-Myc protein was found in
the nucleolar compartment in 78% of the co-transfected cells
(Fig. 4, panel B). We then tested the ability of the N-Myc
d(1–300) protein, unable to interact with ARF (Fig. 3), to be
recruited by ARF.
As shown in Fig. 4B, in the cells co-transected with both
GFP-p14ARF and N-Myc d(1–300) deletion mutants, the twoproteins were found in the nucleoli and nucleoplasm, respec-
tively. These data strengthen our ﬁndings that p14ARF inter-
acts in vivo with N-Myc, and a deletion of the central region
of N-Myc protein strongly impairs interaction with ARF as
well as sub-cellular co-localization in the nucleoli.
3.4. p14ARF N-terminal domain is involved in interaction with
Myc proteins
In the attempt to deﬁne the ARF region involved in Myc
interaction, we subcloned the ARF cDNA regions coding for
aa 1–65 and for aa 65–132 in a FLAG epitope tagged
CMV10 vector. The F:ARF(1–65), F:ARF(65–132) constructs
and the wt F:ARF vectors were transfected alone or in combi-
nation with N-Myc and c-Myc vectors into 293T cells as indi-
cated in Fig. 5A and B. Protein extracts from the transfected
Fig. 4. p14ARF overexpression recruits N-Myc into nucleoli. SK-N-BE cells were co-transfected with GFP-p14ARF and pcDNA3-N-Myc or
pcDNA3-N-Myc d(1–300) by Lipofectamine, as indicated. An example of immunoﬂuorescence microscopy of the cells immunostained with N-Myc
and analyzed by ﬂuorescence microscopy as previously described is shown. At least 150 cells were analyzed in each experiment. Values are means
from three independent experiments. All images were digitally processed using Adobe Photoshop.
Fig. 5. (A) 293T cells were co-transfected with 7 lg each of pcDNA3-c-Myc together with the F:ARF construct or its deletion mutant derivatives
F:ARF (1–65) and F:ARF (65–132). Protein extracts were immunoprecipitated with the c-Myc antibody (lanes 1–3) or a preimmune antiserum IgG
(lanes 4 and 5) as negative control. Co-IP complexes were analyzed by WB with the indicated antibodies. Five percent of the protein inputs were
loaded in lanes 6–8. (B) 293T cells were co-transfected with F:N-Myc together with the F:ARF construct or its deletion mutant derivatives F:ARF(1–
65) and F:ARF(65–132). Protein extracts were immunoprecipitated with the N-Myc antibody (lanes 1–3) or IgG (lanes 4 and 5) as negative control,
as indicated. Co-IP complexes were analyzed by WB with the indicated antibodies. Five percent of the protein inputs were loaded in lanes 6–8.
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or the N-Myc (panel B) antibodies and the coimmunoprecipi-
tated proteins analyzed by WB with c-Myc, N-Myc, Max and
FLAG antibodies as indicated.
The results shown in Figs. 5A and B demonstrate that either
the ARFwt protein or the protein encoding for the ﬁrst 65 aa
interacts with c-Myc and N-Myc, respectively. In contrast, the
ARF C-terminal domain from aa 65 to 132 is impaired in bind-
ing to either Myc proteins. As control of c-Myc and N-Myc
immunoprecipitation, WB with the Max antibody conﬁrmed
the presence of the endogenous Max protein in all the Myc
IP extracts, suggesting that p14ARF associates with N-Myc-
Max heterodimer in vivo and that N-Myc binding to Max
and p14ARF is not mutually exclusive.
3.5. Conclusion
Taken together the data presented in this study demon-
strated that p14ARF is a bona ﬁde N-Myc partner, and thatN-Myc mediated transactivation is inhibited by ARF over-
expression. In addition, ARF over-expression in the neuro-
blastoma SK-N-BE cell line recruits N-Myc into nucleoli.
Mapping of the N-Myc domain involved in ARF binding
reveals that a region between aa 140 and 300 containing the
Myc BoxIII is crucial for N-Myc-ARF binding. Moreover,
the same region is also required for nucleolar co-localization.
These ﬁndings underlie the relevance of the Myc BoxIII
domain in the physiological interaction between the ARF
and N-Myc proteins. Finally, we demonstrated that the N-ter-
minal region of the ARF protein (aa 1–65) is necessary for
ARF binding to both c-Myc and N-Myc proteins.
Myc proteins have been dissected in several biologically
functional domains and an enormous number of studies have
been done trying to give valuable insight into their contribu-
tion to Myc functions [22]. Myc BoxII has been found to be
essential for most Myc functions such as transformation,
apoptosis diﬀerentiation and cell cycle arrest. Deletion of this
S. Amente et al. / FEBS Letters 581 (2007) 821–825 825box dramatically reduces the transactivation function of Myc
[10,22]. However, it has also been found that deletion of
MycBoxII reduces the transcription of most but not all Myc
target genes [23]. Two further Myc homology domains have
been characterized, MycBoxIII and MycBoxIV, and it has
been found that deletion mutants in these regions have defects
in the activation of a variable set of Myc target genes
[10,24,25]. We have found that while the MycBoxII seems to
be dispensable for N-Myc binding to ARF, eﬃcient interaction
between the two proteins requires a region encompassing the
MycBoxIII. However, we cannot exclude the contributory role
of additional N-terminal regions of N-Myc in ARF binding.
How ARF binding to Myc might inhibit its transactivating
functions is unknown. Myc mediated transactivation is the
result of a complex network of protein interactions between
Myc proteins and their co-regulators and regulation of tran-
scription by Myc is supposed to be the consequence of forma-
tion of dedicated Myc protein complexes. Recently, we have
shown that ARF does not possess an intrinsic repression activ-
ity, and as discussed recently ([15] and references therein) it is
likely that ARF binding may alter the association of Myc to
dedicated co-factors either through sterical hindrance or due
to mutually exclusive interactions.
In conclusion, the ﬁndings reported here showing that ARF
negatively regulates N-Myc, in a manner similar to c-Myc,
provide additional evidences of the p53-independent tumor-
suppressor activity of the ARF protein.
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